Durable reductions in circulating angiotensinogen and blood pressure six months after single doses of ALN-AGT, an RNA interference therapeutic targeting hepatic …

S Huang, J Taubel, S Casey, PM Leung, DJ Webb… - Circulation, 2021 - Am Heart Assoc
… effects of ALN-AGT six months after single-dose administration. … of ALN-AGT to hypertensive
patients was generally well tolerated and resulted in profound reductions in serum AGT and …

Safety, pharmacodynamics, and blood pressure effects of ALN-AGT, an RNA interference therapeutic targeting angiotensinogen, in a randomized single ascending …

SA Huang, J Taubel, G Fiore, P Dewland… - Journal of …, 2021 - journals.lww.com
ALN-AGT, a subcutaneous investigational RNA interference (RNAi) therapeutic targeting
hepatic AGT … to assess the safety and tolerability of ALN-AGT, we conducted a multicenter study …

[PDF][PDF] … with a RNA interference (RNAi) therapeutic targeting angiotensinogen in hypertensive patients: interim results from a first-in-human phase 1 study of ALN …

S Desai - Circulation, 2020 - academia.edu
… – Severe and serious AE of prostate cancer reported in 1 patient who received 200 mg
ALN-… effect of ALN-AGT01 and potential durability of effect in lowering AGT beyond 3 months …

Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review

P Ranasinghe, ML Addison, JW Dear… - British Journal of …, 2023 - Wiley Online Library
RNA interference technology, using synthetic structurally well-defined short double-stranded
RNA (small interfering RNA [… ALN-HSD is currently under evaluation in Phase I trials for this …

Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease

EO Cruz-López, D Ye, C Wu, HS Lu, E Uijl… - …, 2022 - Am Heart Assoc
RNA translation and small interfering RNA (siRNA) that function via the RNA interference
vehicle or AGT small interfering RNA (siRNA) during the final 3 wk (n=7 per group). Middle, …

Therapeutic RNA-silencing oligonucleotides in metabolic diseases

A Goga, M Stoffel - Nature Reviews Drug Discovery, 2022 - nature.com
RNA interference (RNAi), target degradation by RNase H-mediated cleavage, splicing
modulation, noncoding RNA … Initially, an intravenously administered LNP-formulated siRNA (ALN-…

COUNTERACTING ANGIOTENSINOGEN SMALL INTERFERING RNA-MEDIATED ANTIHYPERTENSIVE EFFECTS WITH REVERSIR

EC López, D Ye, R Van Veghel, IM Garrelds… - Journal of …, 2024 - journals.lww.com
AGT-RVR had no impact on valsartan-induced AGT reduction. Post-AGR-RVR, a second
AGT… In summary, AGT-RVR is a highly selective tool for AGT and BP restoration in SHR. These …

Brain renin–angiotensin system and liver-directed siRNA targeted to angiotensinogen

CM Ferrario, L Groban, H Wang, S Ahmad - Clinical Science, 2021 - portlandpress.com
… Second, it is unclear whether oligonucleotides that function via the RNA interference (RNAi)…
AGT siRNA [ALN-AGT RNAi] [30]. Briefly, patients receiving the investigational ALN-AGT

Gene silencing by RNA interference: a review

S Malakondaiah, A Julius, D Ponnambalam… - Genome Instability & …, 2024 - Springer
… , an RNAi therapeutic targeting angiotensinogen (AGT), in … the combination of ALN-APP
with BIIB080 or ALN-APP and … to track the therapeutic effects of ALN-APP and BIIB080 will be …

RNAi therapeutic and its innovative biotechnological evolution

Y Weng, H Xiao, J Zhang, XJ Liang, Y Huang - Biotechnology advances, 2019 - Elsevier
… of oligonucleotide therapeutic functioned via RNA interference (RNAi), was approved by the
… called small interfering RNA (siRNA). siRNA is a class of double-stranded RNA molecule, 19…